Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol® (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA™ (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily

NCT01915901 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01915901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01915901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol® (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA™ (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
December 31, 2013
Enrollment
175 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy